Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
View/ Open
Date
2019-01-01ICR Author
Author
Zafeiriou, Z
Bianchini, D
Chandler, R
Rescigno, P
Yuan, W
Carreira, S
Barrero, M
Petremolo, A
Miranda, S
Riisnaes, R
Rodrigues, DN
Gurel, B
Sumanasuriya, S
Paschalis, A
Sharp, A
Mateo, J
Tunariu, N
Chinnaiyan, AM
Pritchard, CC
Kelly, K
de Bono, JS
Type
Journal Article
Metadata
Show full item recordAbstract
Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, and that such genomic aberrations are synthetically lethal with both poly(ADP)-ribose polymerase inhibition and platinum, has increased interest in the utilisation of these drugs against a subset of these diseases. Here in we report three patients with advanced castration-resistant PCa with HRD defects having exceptional responses to carboplatin.
Collections
Subject
Humans
Adenocarcinoma
Carboplatin
Antineoplastic Agents
Pedigree
Adult
Aged
Middle Aged
Male
DNA Repair-Deficiency Disorders
Recombinational DNA Repair
Prostatic Neoplasms, Castration-Resistant
Research team
Cancer Biomarkers
Prostate Cancer Targeted Therapy Group
Translational Therapeutics
Language
eng
Date accepted
2018-09-27
License start date
2019-01
Citation
European urology, 2019, 75 (1), pp. 184 - 192
Publisher
ELSEVIER SCIENCE BV